Invention Application
- Patent Title: FC-OPTIMIZED ANTI-CD25 FOR TUMOR SPECIFIC CELL DEPLETION
-
Application No.: US16494962Application Date: 2018-03-03
-
Publication No.: US20200010554A1Publication Date: 2020-01-09
- Inventor: Anne Goubier , Josephine Salimu , Kevin Moulder , Beatriz Goyenechea Corzo , Pascal Merchiers , Sergio Quezada , Karl Peggs , Frederick Arce Vargas , Isabelle Solomon
- Applicant: Tusk Therapeutics Ltd. , Cancer Research Technology Limited
- Priority: EP17161717.8 20170317; GB1710879.6 20170706; GB1714429.6 20170907
- International Application: PCT/EP2018/056312 WO 20180303
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C07K14/55
Abstract:
The present disclosure relates to use of an anti-CD25 antibody, not inhibiting IL-2-CD25 interaction, with enhanced binding to activating Fc gamma Rs that lead to effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Combination with anti-programmed cell death protein-1 antibodies further improves tumor rejection.
Public/Granted literature
Information query
